BOSTON SCIENTIFIC CORPORATION vs ResMed Inc., two Medical Devices stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BSX and RMD diverge most: on implied growth (priced in), BSX reads +1.6% and RMD reads +8.5%; on debt / equity, BSX reads 0.50 and RMD reads 0.10. The rest of the comparable metrics sit closer together. On valuation, today's BSX price has a different growth bar priced in than RMD (+1.6% implied for BSX vs +8.5% for RMD); the higher figure is the steeper assumption to clear, not a better or worse stock. What BSX's price implies is a bet that sits within the historical range (whole-company basis). What RMD's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | BSX | RMD |
|---|---|---|
| Price | $42.74 | $230.14 |
| Market cap | $63.0B | $33.5B |
| Sector | Medical Devices | Medical Devices |
| Stage | Growth | Mature |
| Implied growth (priced in) | +1.6% | +8.5% |
| P/E | 17.3 | 22.1 |
| P/B | 2.50 | 5.09 |
| P/S | 3.00 | 5.93 |
| EV/EBITDA | 13.8 | 15.7 |
| Revenue growth | +13.8% | +9.9% |
| Gross margin | 70.7% | 58.8% |
| Operating margin | 21.6% | 30.7% |
| Net margin | 17.5% | 26.9% |
| Return on equity | 14.6% | 23.1% |
| Return on assets | 8.1% | 17.0% |
| Return on invested capital | 9.4% | 21.1% |
| FCF yield | 5.8% | 4.9% |
| Dividend yield | — | 1.0% |
| Debt / equity | 0.50 | 0.10 |
| Current ratio | 1.24 | 3.10 |
| Altman Z (solvency) | 6.83 | 8.32 |
| Piotroski F (quality) | 8 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.